Bollerslev J, Nielsen H K, Storm T, Mosekilde L
Department of Internal Medicine, Svendborg Hospital, Denmark.
Bone. 1988;9(6):355-9. doi: 10.1016/8756-3282(88)90116-0.
The nuclear uptake of (3H)-1,25 dihydroxyvitamin D3 in freshly isolated human monocytes and the serum levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were investigated in 13 patients with autosomal dominant osteopetrosis and in sex- and age-matched controls. Seven patients had type I osteopetrosis characterized by diffuse, symmetrical osteosclerosis with pronounced sclerosis of the skull and increased thickness of the cranial vault. The other six patients had type II with "Rugger Jersey Spine" and "endobones" as characteristic findings. In type I osteopetrosis the serum 1,25-dihydroxyvitamin D was significantly reduced (p less than 0.05), whereas serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D receptor binding were normal. In type II osteopetrosis the serum vitamin D metabolites were normal, as was the maximal binding capacity (Bmax) of 1,25-dihydroxyvitamin D to the nuclear receptor. The dissociation constant (Kd), however, was significantly increased (p less than 0.01) indicating a modest resistance to 1,25-dihydroxyvitamin D. It is concluded that a general end-organ resistance to 1,25-dihydroxyvitamin D at the receptor level does not exist in type I osteopetrosis, but may contribute to some of the radiological and biochemical findings in type II.
对13例常染色体显性遗传性骨硬化症患者及性别和年龄匹配的对照组,研究了新鲜分离的人单核细胞对(3H)-1,25二羟维生素D3的核摄取以及血清25-羟维生素D和1,25-二羟维生素D水平。7例患者为I型骨硬化症,其特征为弥漫性、对称性骨硬化,颅骨明显硬化,颅穹窿厚度增加。另外6例患者为II型,特征性表现为“橄榄球运动员衫脊柱”和“内生骨”。I型骨硬化症患者血清1,25-二羟维生素D显著降低(p<0.05),而血清25-羟维生素D和1,25-二羟维生素D受体结合正常。II型骨硬化症患者血清维生素D代谢产物正常,1,25-二羟维生素D与核受体的最大结合容量(Bmax)也正常。然而,解离常数(Kd)显著升高(p<0.01),表明对1,25-二羟维生素D有一定抗性。结论是,I型骨硬化症不存在受体水平上对1,25-二羟维生素D的普遍终末器官抗性,但可能是II型骨硬化症某些放射学和生化表现的原因之一。